our Founder
Mark Siracusa, PhD
Mark is Associate Professor in the Department of Medicine and the Center for Immunity and Inflammation at Rutgers New Jersey Medical School where his research focuses on Mechanisms that promote immunity to helminth parasites and the development of allergic inflammation.
He received his PhD from Johns Hopkins in Molecular, Microbiology and Immunology and did his Post doc at the University of Pennsylvania under David Artis.
Mark has published in multiple prestigious journals including The Journal of Experimental Medicine, Nature Immunology, PLOS Pathogens, and Cell Reports and has received multiple grants, including 3 current R01 grants from the NIH.
Leadership
Nicholas Shubin, PhD
Chief Executive Officer
Nick received his PhD from Brown University in Pathobiology and did his postdoc at Seattle Children’s Research Institute under Adrian Piliponsky, where he focused on understanding the roles of mast cells and basophils in acute inflammatory diseases. Nick has published research in journals such as Nature Immunology and Journal of Allergy and Clinical Immunology. Before joining NemaGen, Nick worked in Business Development for an immunoassay biotechnology company.
Research Team
Jianya Peng, PhD
Principle Scientist
10+ years of experience in studying host immune responses. Dr. Peng leads NemaGen's in-house drug development programs.
Scientific and business advisory board
David Artis, PhD
Martin Devenport, PhD, MBA
Martin Devenport, PhD, MBA
Director, Jill Roberts Institute for Research in Inflammatory Bowel Disease and the Michael Kors Professor of Immunology, Department of Medicine at Weill Cornell
Martin Devenport, PhD, MBA
Martin Devenport, PhD, MBA
Martin Devenport, PhD, MBA
10+ years of corporate experience in the biotech industry, with experience in all aspects of drug development, including R&D, GMP manufacturing, regulatory and clinical trials
John Piwinski, PhD
Martin Devenport, PhD, MBA
Matthew Giannetti, MD
Expertise in small molecule drug discovery with over 30 years of experience in medicinal chemistry
Matthew Giannetti, MD
Adrian Piliponsky, PhD
Matthew Giannetti, MD
Associate Director of the Brigham and Women's Hospital Mastocytosis Center. Dr. Giannetti treats patients with many mast cell disorders, including systemic mastocytosis.
Adrian Piliponsky, PhD
Adrian Piliponsky, PhD
Adrian Piliponsky, PhD
University of Washington Professor and Principal Investigator within the Center for Immunity and Immunotherapeutics at Seattle Children's Research Institute. Dr. Piliponsky is a renown mast cell biology expert.
Peter Grebow, PhD
Adrian Piliponsky, PhD
Adrian Piliponsky, PhD
Former Senior Manager for many biotech companies, including Senior VP of Worldwide Business Development at Cephalon; VP, Drug Development for Rorer Central Research; and Executive VP of Research and Development at Eagle Pharmaceuticals.
Board of Directors
Mark Siracusa, PhD
Mark Siracusa, PhD
Mark Siracusa, PhD
President of NemaGen Discoveries
James Golubieski
Mark Siracusa, PhD
Mark Siracusa, PhD
President of Foundation Venture Capital Group